SOC Cohort Rivaroxaban Cohort
N=(192) N=(64)
N/Mean %/SD N/Mean %/SD p-value
PE-related Clinical Outcomes during the 90-day follow-up period
Recurrent VTE 9 4.7% 2 3.1% 0.5935
Time to first VTE, days 47.6 24.6 29.5 26.2 0.3763
Major Bleeding 2 1.0% 0 0.0% 0.4124
Time to first Major Bleeding, days 5.00 2.8
Death 3 1.6% 0 0.0% 0.3145
Time to Death, days 35.33 30.4
90-day Follow-up Diagnostic tests
CTA 63 32.8% 17 26.6% 0.3502
ECHO 14 7.3% 2 3.1% 0.233
VQ Scan 6 3.1% 1 1.6% 0.5068
Venous Doppler Ultrasound 56 29.2% 16 25.0% 0.5208